Skip to main content
Premium Trial:

Request an Annual Quote

Silence Is Not Always Golden

For years, Genome Technology has been poking at the good people of GE Healthcare to let us in on their plans for next-gen sequencing. Now, it seems, the muzzle is off.

In a post on the company's "From Edison's Desk" blog, John Nelson -- best known in this field as one of the minds behind TempliPhi -- writes about his team's work developing a next-gen sequencing platform. After a discussion of how the technology works, Nelson adds, "And yes, if you were wondering whether we are thinking of winning the X-Prize some day using this method, we do hope to. But that's a long way off just now."

Hmm. Do we buy it? GTO wouldn't be surprised if they're closer than they let on.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.